Douglas Clark
Chief Pathologist, Life Sciences & Diagnostics Markets Group Agilent Technologies
Seminars
Thursday 25th September 2025
Leveraging AI Diagnostics for Digital Pathology: Biomarker Screening & Patient Outcome Prediction from Clinical Trials to Clinical Routine
12:40 pm
- AI Solutions for Biomarker Detection and Patient Identification: Explore how Owkin’s AI solutions enable reliable, scalable biomarker screening and patient outcome prediction support patient identification strategies in clinical trials and informing treatment decisions in routine care
- Advancing IHC with Foundation Models and CDx Applications: Discover Owkin IHC approaches geared towards augmenting pathologist interpretations and supporting the development of CDx tools for ADCs, improving patient selection and access to targeted therapies
Wednesday 24th September 2025
Is AI-Driven Analysis of Tissue Features that Predict Response to Therapy Reshaping Large Molecule Development?
11:20 am
- Target biology can be deeply mapped by assessing the range of expression from subcellular to population level
- Can AI-driven quantification of target expression predict response for ADCs and other antibody-based therapeutics?
- Important considerations for evaluating AI-integrated companion diagnostics development
